For hofte BMD havde 90, 0% (p < 0, 001) af de patienter, som fik 150 mg én gang om måneden og 76, 7% af patienterne, som fik ibandronsyre 2, 5 mg daglig, stigninger i hofte BMD over eller lig baseline efter et år.
For total hip BMD, 90.0% (p < 0.001) of patients receiving Bonviva 150 mg once monthly and 76.7% of patients receiving ibandronic acid 2.5 mg daily had total hip BMD increases above or equal to baseline at one year.